No Data
No Data
Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity
Verastem Is Maintained at Buy by Truist Securities
Express News | Verastem Inc : Truist Securities Cuts Target Price to $15 From $18
Express News | HC Wainwright & Co. Maintains Buy on Verastem, Lowers Price Target to $7
Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism
Express News | Verastem, Inc. : H.c. Wainwright Cuts Target Price to $7 From $17.5
No Data